Julia Gesine Fricke
Postdoctoral Scholar, Radiology
Bio
Dr. Julia G. Fricke is a Swiss board-certified nuclear medicine physician-scientist and Postdoctoral Scholar in the Department of Radiology at Stanford University School of Medicine, supported by a Swiss National Science Foundation (SNSF) Postdoc.Mobility Fellowship.
Her research focuses on theranostics and the clinical translation of novel radiopharmaceuticals, with a particular interest in targeted radionuclide therapy and molecular imaging in oncology. During her clinical and research training at University Hospital Basel, Switzerland, she contributed to the first-in-human clinical evaluation of the somatostatin receptor antagonist [¹⁶¹Tb]Tb-DOTA-LM3 for neuroendocrine tumor therapy, as well as the clinical investigation of GLP-1 receptor PET/CT using [⁶⁸Ga]Ga-DOTA-exendin-4 for insulinoma localization. Her research has been recognized with several distinctions, including the Marie Curie Award at EANM 2024 and the Young Authors Award at EANM 2026.
At Stanford, her research focuses on long-axial-field-of-view PET/CT and its potential to advance the clinical translation of emerging radiopharmaceuticals. Her long-term research interests include the development and clinical translation of innovative molecular imaging and targeted radionuclide therapy strategies.
Honors & Awards
-
Young Authors Award, EANM (2026)
-
SNSF Postdoc.Mobility Fellowship, Swiss National Science Foundation (2026)
-
EANM Travel Award, Novartis (2026)
-
Best Oral Presentation, SGNM (2024)
-
Image of the Month, EJNMMI (2024)
-
Marie Curie Award, EANM (2024)
Boards, Advisory Committees, Professional Organizations
-
Member, ENETS (2026 - Present)
-
Member, EANM (2024 - Present)
-
Member, SGNM (2021 - Present)
Professional Education
-
Doctor of Medicine, Ludwig Maximilian Universitat Munchen (2022)
-
Staatsexamen, Ludwig Maximilian Universitat Munchen (2020)
-
Fellowship, University Hospital Basel, Switzerland, Radiology (2026)
-
Board Certification, Swiss Medical Association, Nuclear Medicine (2026)
-
Residency, University Hospital Basel, Switzerland, Nuclear Medicine (2024)
-
MD, Ludwig-Maximilians-University, Munich, Germany, Medicine (2020)
All Publications
-
Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
2026; 67 (3): 416-422
Abstract
The goal of this phase 0 study was to determine the absorbed doses in tumors and relevant organs after a test injection of [161Tb]Tb-DOTA-LM3 and [177Lu]Lu-DOTATOC in the same cohort of patients with grade 1 and 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Methods: In this randomized, crossover, prospective, single-center, open-label phase 0 study, 8 patients received 1 GBq of [161Tb]Tb-DOTA-LM3 and 1 GBq of [177Lu]Lu-DOTATOC, with a 4-wk interval between injections. Quantitative SPECT/CT imaging was performed 3, 24, 72, and 168 h after administration of each radiopharmaceutical to calculate tumor and organ absorbed doses (3-dimensional dosimetry using a Monte Carlo-based ordered-subset expectation maximization algorithm). Results: After injection of 1 GBq of [161Tb]Tb-DOTA-LM3, SPECT/CT revealed excellent image quality with intense tumor uptake in all patients and a median of the mean effective tumor half-life of 103 h (range, 56-152 h) for [161Tb]Tb-DOTA-LM3 and 83 h (range, 30-122 h) for [177Lu]Lu-DOTATOC (P = 0.012). The medians of the mean tumor absorbed doses of [161Tb]Tb-DOTA-LM3 and [177Lu]Lu-DOTATOC were 36.6 Gy/GBq (range, 15-196 Gy/GBq) and 7.0 Gy/GBq (range, 2.4-14.2 Gy/GBq), respectively (P = 0.008). The median kidney and bone marrow absorbed doses were 2.4 Gy/GBq (range, 1.8-3.1 Gy/GBq) and 0.31 Gy/GBq (range, 0.24-0.48 Gy/GBq) for [161Tb]Tb-DOTA-LM3 and 0.6 Gy/GBq (range, 0.4-0.8 Gy/GBq) and 0.04 Gy/GBq (range, 0.03-0.06 Gy/GBq) for [177Lu]Lu-DOTATOC, respectively (both P = 0.008). According to Common Terminology Criteria for Adverse Events version 5.0, grade 1-3 treatment-emergent adverse events occurred in 6 of 8 patients after administration of 1 GBq of [161Tb]Tb-DOTA-LM3. Conclusion: [161Tb]Tb-DOTA-LM3 showed a 7.6-fold-higher median tumor absorbed dose than that of [177Lu]Lu-DOTATOC. The tumor-to-bone marrow absorbed dose ratio was in the same range for [161Tb]Tb-DOTA-LM3 as for [177Lu]Lu-DOTATOC. The administration of 1 GBq of [161Tb]Tb-DOTA-LM3 was safe for all patients, without relevant adverse events.
View details for DOI 10.2967/jnumed.125.270654
View details for PubMedID 41381241
View details for PubMedCentralID PMC12955530
-
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum.
European journal of nuclear medicine and molecular imaging
2024; 51 (8): 2517-2519
View details for DOI 10.1007/s00259-024-06641-w
View details for PubMedID 38448550
View details for PubMedCentralID PMC11178597
-
<SUP>68</SUP>Ga-DOTA-exendin-4 PET/CT for insulinoma localization in patients with negative or inconclusive conventional imaging
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
2026; 111 (11): 3163-3171
Abstract
Insulinomas are the main cause of endogenous hyperinsulinemic hypoglycemia (EHH) in adults, with surgery as the only cure. Pancreas-preserving surgery is preferred, making precise preoperative localization crucial. GLP-1R-targeted imaging, such as [68Ga]Ga-DOTA-exendin-4 PET/CT, outperforms other imaging procedures for insulinoma localization.To investigate the performance and clinical impact of [68Ga]Ga-DOTA-exendin-4 PET/CT for the detection of insulinomas in patients with EHH and prior negative or inconclusive conventional imaging.In this retrospective, real-world, dual-center imaging study, 101 patients with biochemically proven EHH and/or a positive Whipple's triad underwent [68Ga]Ga-DOTA-exendin-4 PET/CT at two tertiary centers between April 2017 and March 2024. Among these, 58 patients with prior negative or inconclusive conventional imaging constituted the primary analysis cohort. Endpoints: Insulinoma detection rate and sensitivity by [68Ga]Ga-DOTA-exendin-4 PET/CT after negative or inconclusive conventional imaging and impact on clinical management.Among the 58 patients with prior negative or inconclusive conventional imaging, [68Ga]Ga-DOTA-exendin-4 PET/CT was positive in 42 patients, corresponding to a detection rate of 72% (95% CI, 59-83%). Thirty patients subsequently underwent PET/CT-guided surgery. Overall, 32 patients had histological verification (including two PET/CT-negative cases), corresponding to a sensitivity of 93.8% (95% CI, 79-99%).In real-world clinical practice, [68Ga]Ga-DOTA-exendin-4 PET/CT provides a high detection rate of 72% for localizing insulinomas, including one case of diffuse nesidioblastosis in patients with EHH and prior negative or inconclusive conventional imaging, thereby enabling PET/CT-guided surgical approaches. These findings underscore the substantial clinical impact of GLP-1R-targeted PET/CT on patient management and prognosis.
View details for DOI 10.1210/clinem/dgag214
View details for Web of Science ID 001782454100001
View details for PubMedID 42168767
View details for PubMedCentralID PMC13671787
-
Systematic review and meta-analysis of the efficacy and safety of [177Lu]Lu-edotreotide ([177Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors.
Journal of neuroendocrinology
2026; 38 (1): e70103
Abstract
[177Lu]Lu-edotreotide is a radiopharmaceutical therapy (RPT) targeting somatostatin receptors, which are commonly overexpressed on neuroendocrine tumors (NETs). This systematic literature review and meta-analysis describes the efficacy and safety of [177Lu]Lu-edotreotide in patients with NETs. To date, there has been no meta-analysis of data for this specific RPT. PubMed, EMBASE, Cochrane databases, and abstracts from select congresses were searched for eligible studies (February/October 2024). Meta-analysis was performed using fixed and random-effects models. The primary objective was to evaluate the efficacy of [177Lu]Lu-edotreotide in terms of objective response rate (ORR; complete + partial response) in the subgroup of patients with gastro-enteropancreatic NETs (GEP-NETs) and those with any NETs, irrespective of origin (All-NETs). Secondary outcomes included disease control rate (DCR; best overall response of complete response + partial response + stable disease), median progression-free survival (mPFS), and median overall survival (mOS). Unpublished/updated data were requested from the investigators of the included publications where needed to provide missing information/enable evaluation of additional outcomes. Safety/tolerability data for [177Lu]Lu-edotreotide were also reviewed. Eight eligible studies were identified for inclusion in the meta-analysis, all in the advanced disease setting (5/8 included patients with progressive NETs). Most patients had grade 1/2 NETs (grade 1: 11%-63%; 2: 30%-79%; 3: 4%-11%). Updated data were provided for four of these studies. Overall, ORR and DCR were reported in six studies (GEP-NETs, n = 222; All-NETs, n = 423), mPFS in five studies (GEP-NETs, n = 294; All-NETs, n = 267), and mOS in six studies (GEP-NETs, n = 256; All-NETs, n = 408). Meta-analysis revealed consistently high heterogeneity (I2 >70%) across outcomes/patient populations. Patients with GEP-NETs appeared to have better outcomes than those with All-NETs in terms of ORR (34% vs. 19%), DCR (78% vs. 57%), mPFS (24.9 vs. 18.6 months), and mOS (44.8 vs. 39.1 months), respectively. Safety/tolerability data were inconsistently reported, but grade 3/4 toxicities were rarely noted during [177Lu]Lu-edotreotide treatment. These results support the effectiveness and safety of [177Lu]Lu-edotreotide as a treatment for patients with advanced NETs and suggest a potentially more favorable prognosis for those with GEP-NETs than for the broader All-NETs population. However, these results should be interpreted with caution due to the high level of heterogeneity. Encouraging ORRs and high DCRs were noted, indicating that [177Lu]Lu-edotreotide effectively stabilized disease in most patients. Although safety/tolerability data were inconsistently published across studies, [177Lu]Lu-edotreotide was generally well tolerated. Overall, these findings suggest that the efficacy and safety of [177Lu]Lu-edotreotide are in line with those reported for other RPTs in similar clinical settings. Clinical Trial Registration: PROSPERO 2024 CRD42024518028.
View details for DOI 10.1111/jne.70103
View details for PubMedID 41204752
View details for PubMedCentralID PMC12799327
-
Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imaging
EJNMMI PHYSICS
2025; 12 (1)
View details for DOI 10.1186/s40658-025-00792-x
View details for Web of Science ID 001560491700001
-
Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting.
European journal of nuclear medicine and molecular imaging
2024; 51 (13): 4049-4061
Abstract
[177Lu]Lu-DOTATATE is an established somatostatin receptor (SSTR) agonist for the treatment of metastasized neuroendocrine neoplasms, while the SSTR antagonist [177Lu]Lu-DOTA-LM3 has only scarcely been employed in clinics. Impressive preclinical data obtained with [161Tb]Tb-DOTA-LM3 in tumor-bearing mice indicated the potential of terbium-161 as an alternative to lutetium-177. The aim of the present study was to compare the tolerability of 161Tb- and 177Lu-based DOTA-LM3 and DOTATATE in immunocompetent mice.Dosimetry calculations were performed based on biodistribution data of the radiopeptides in immunocompetent mice. Treatment-related effects on blood cell counts were assessed on Days 10, 28 and 56 after application of [161Tb]Tb-DOTA-LM3 or [161Tb]Tb-DOTATATE at 20 MBq per mouse. These radiopeptides were also applied at 100 MBq per mouse and the effects compared to those observed after application of the 177Lu-labeled counterparts. Bone marrow smears, blood plasma parameters and organ histology were assessed at the end of the study.The absorbed organ dose was commonly higher for the SSTR antagonist than for the SSTR agonist and for terbium-161 over lutetium-177. Application of a therapeutic activity level of 20 MBq [161Tb]Tb-DOTA-LM3 or [161Tb]Tb-DOTATATE was well tolerated without major hematological changes. The injection of 100 MBq of the 161Tb- and 177Lu-based somatostatin analogues affected the blood cell counts, however. The lymphocytes were 40-50% lower in treated mice compared to the untreated controls on Day 10 irrespective of the radionuclide employed. At the same timepoint, thrombocyte and erythrocyte counts were 30-50% and 6-12% lower, respectively, after administration of the SSTR antagonist (p < 0.05) while changes were less pronounced in mice injected with the SSTR agonist. All blood cell counts were in the normal range on Day 56. Histological analyses revealed minimal abnormalities in the kidneys, liver and spleen of treated mice. No correlation was observed between the organ dose and frequency of the occurrence of abnormalities.Hematologic changes were more pronounced in mice treated with the SSTR antagonist than in those treated with the SSTR agonist. Despite the increased absorbed dose delivered by terbium-161 over lutetium-177, [161Tb]Tb-DOTA-LM3 and [161Tb]Tb-DOTATATE should be safe at activity levels that are recommended for their respective 177Lu-based analogues.
View details for DOI 10.1007/s00259-024-06827-2
View details for PubMedID 39046521
View details for PubMedCentralID PMC11527941
https://orcid.org/0009-0008-0030-9565